Acurx Pharmaceuticals Inc（ACXP）财务数据ACXPAcurx Pharmaceuticals Inc

Evaluating the bottom line, Acurx Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -128.11%, provide a clear picture of how effectively ACXP converts its operational activities into shareholder value.

In the context of the broader market, ACXP competes directly with industry leaders such as CNSP and BGMS. With a market capitalization of $5.83M, it holds a leading position in the sector. When comparing efficiency, ACXP's gross margin of N/A stands against CNSP's N/A and BGMS's 23.51%. Such benchmarking helps identify whether Acurx Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Acurx has shown a consistent increase in cash reserves, ending Q2 2026 with $10.7 million, up from $7.6 million in Q1 2026. However, the company continues to report net losses, with a loss of $2.3 million in Q2 2026, and a diluted loss per share of $0.53, indicating challenges in achieving profitability in the short term.